| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.smslife.in | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 213.53 Cr. | |
| Earnings per share (EPS) | 44.84 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 15.75 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 35.15 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 427.40 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 1.65 | Calculated using Price: 706.30 |
| Dividend Yield | 0.00 | Period Ending 2020-03 |
| No. of Shares Subscribed | 0.30 Cr. | 3,023,287 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
SMS Lifesciences is a global player in Active Pharmacy Ingredients (API) manufacturing having a strong research and manufacturing team supported by state of the art facilities. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having product list spreading across an array of therapeutic segments. The company has two API facilities known as Khazipally unit and Jeedimetla unit. Both these units are located in the Hyderabad. The company aims at achieving Quality excellence and customer satisfaction through Good Manufacturing practices and strives for continual improvement. All its manufacturing facilities are ISO:9001 certified and are WHO-GMP compliant. SMS Lifesciences has developed fully equipped quality control cells at all the manufacturing facilities manned by experienced and qualified staff. SMS Lifesciences has the required capabilities and infrastructure to ensure full operation of the quality function from Raw material analysis to in process analysis and analysis of final products. Business area of the company: SMS Lifesciences India is presently engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of Organic & Inorganic Chemicals, Pharmaceuticals, API and Intermediates. |
||
Company Profile
SMS Lifesciences is a global player in Active Pharmacy Ingredients (API) manufacturing having a strong research and manufacturing team supported by state of the art facilities. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having product list spreading across an array of therapeutic segments.
The company has two API facilities known as Khazipally unit and Jeedimetla unit. Both these units are located in the Hyderabad. The company aims at achieving Quality excellence and customer satisfaction through Good Manufacturing practices and strives for continual improvement. All its manufacturing facilities are ISO:9001 certified and are WHO-GMP compliant.
SMS Lifesciences has developed fully equipped quality control cells at all the manufacturing facilities manned by experienced and qualified staff. SMS Lifesciences has the required capabilities and infrastructure to ensure full operation of the quality function from Raw material analysis to in process analysis and analysis of final products.
Business area of the company:
SMS Lifesciences India is presently engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of Organic & Inorganic Chemicals, Pharmaceuticals, API and Intermediates.
| 1 Day |
|
+0.14% |
| 1 Week |
|
-3.45% |
| 1 Month |
|
-7.26% |
| 3 Month |
|
+19.66% |
| 6 Month |
|
+26.67% |
| 1 Year |
|
+114.28% |
| 2 Year |
|
+76.53% |
| 5 Year |
|
| 2 years | 2019-03 | 2020-03 | |
| Return on Equity (%) | 16.78 | 9.17 | |
| Return on Capital Employed (%) | 20.14 | 11.91 | |
| Return on Assets (%) | 6.45 | 3.83 |
| Particulars | 2 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 106 | 116 | |
| Non Curr. Liab. | 39 | 50 | |
| Curr. Liab. | 132 | 90 | |
| Minority Int. | |||
| Equity & Liab. | 276 | 256 | |
| Non Curr. Assets | 128 | 146 | |
| Curr. Assets | 149 | 110 | |
| Misc. Exp. not W/O | |||
| Total Assets | 276 | 256 |
| Particulars | 2 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 378 | 261 | |
| Other Income | 3 | 2 | |
| Total Income | 380 | 263 | |
| Total Expenditure | -343 | -235 | |
| PBIDT | 37 | 28 | |
| Interest | -6 | -5 | |
| Depreciation | -6 | -8 | |
| Taxation | -8 | -4 | |
| Exceptional Items | |||
| PAT | 18 | 10 |
| Particulars | 2 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 30 | 15 | |
| Cash Fr. Inv. | -44 | -27 | |
| Cash Fr. Finan. | 15 | 12 | |
| Net Change | 1 | 0 | |
| Cash & Cash Eqvt | 2 | 2 |
|
Fri, 16 Jul 2021
Shareholding for the Period Ended June 30 2021 SMS Lifesciences India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here |
||||||||||||||
|
Fri, 16 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
|
||||||||||||||
|
Fri, 16 Jul 2021
Consolidated Related Party Transactions [H2-F21] Disclosure as per Reg. 23 (9) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 |
| Fri, 30 Jul 2021 |
Both SRS And ARS Above Zero
|
+DI Crossing -DI From Above
|
Stochastic %K Crossing %D from Below
|
Stochastic In Oversold Zone
|
Price Nearing SuperTrend Support
|
Equities
M.F.
Sectors